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For several years, the first line of treatment of glioblastoma (GB) patients is based on
surgical resection followed by fractioned radiotherapy with concomitant and adjuvant
chemotherapy with temozolomide (TMZ). The effectiveness of this treatment is very
limited due to the development by tumor cells of mechanisms of resistance to TMZ
such as over-expression of O6-methylguanine DNA methyltransferase (MGMT),
epidermal growth factor receptor (EGFR) and galectin-1. In this study, we
hypothesized that the targeting of MGMT, EGFR and galectin-1 (alone or in
combination) by specifics siRNAs carried by chitosan-lipid nanocapsules (chitosan-
LNCs) could enhance the sensitivity of U87MG cells to TMZ. We showed in vitro that
(i) anti-MGMT and (ii) anti-EGFR or anti-galectin-1 siRNAs decreased significantly the
expression of their corresponding proteins and increased the sensitivity of U87MG
cells to TMZ. Additionally, the sensitivity of U87MG/MGMT- cells to TMZ was
significantly increased when anti-EGFR and anti-galectin-1 siRNAs were combined
with a percentage of living cells of 17.8±1.6% at 0.5 mg/mL concentration of TMZ. The
combination of anti-MGMT siRNAs with either anti-EGFR or anti-galectin-1 siRNAs
enhanced the sensitivity of U87MG/MGMT+ cells to TMZ in comparison to their
separately use. No difference was observed between the association of the three
siRNAs and other associations. At 0.5 mg/mL concentration of TMZ, the percentage of
living cells decreased from 55.1±1.9% to 36.0±4.1% for anti-MGMT alone and the
combination of anti-MGMT/anti-galectin-1/anti-EGFR siRNAs, respectively. These
siRNA nanovectors represent a good alternative to enhance the effectiveness of the
standard treatment of GB. This method could be implemented in future preclinical
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